/
Respiratory
Bronchiectasis
18
Pipeline Programs↗
23
Active Trials↗
14
Companies Involved↗
Bronchiectasis is an emerging landscape with 18 programs across 14 companies. The most active players are Boehringer Ingelheim, Chiesi Farmaceutici S.p.A., GSK. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical13
Phase 1
No programs
Phase 33
Approved
No programs
Analysis
Modality Breakdown
93%
Small molecule
14 of 15 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 89% of 18 pipeline programs.
Analysis
Trial Status
77
clinical trials
Completed31 · 40%
Unknown status19 · 25%
Recruiting18 · 23%
Not yet recruiting3 · 4%
Terminated3 · 4%
Active, not recruiting1 · 1%
Other2 · 3%
Clinical Trials
Trial Activity
77 trials
Benefits of Inhalation of Hypertonic Saline Solution Prior to Physiotherapy ELTGOL Technique in Bronchiectasis
Recruiting·IInstitut d'Investigació Biomèdica de Girona Dr. Josep Trueta·Phase 3·NCT06443658·57 enrolled
Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation of Bronchiectasis
Recruiting·—·Phase 4·NCT06209047·315 enrolled
HFNC in Management of Bronchiectasis Exacerbation
Recruiting·—·N/A·NCT05741697·20 enrolled
Research on the Mechanism Affecting Progression of Bronchiectasis
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT05731427·150 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)